174 related articles for article (PubMed ID: 28186965)
1. Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer.
Maltoni R; Casadio V; Ravaioli S; Foca F; Tumedei MM; Salvi S; Martignano F; Calistri D; Rocca A; Schirone A; Amadori D; Bravaccini S
Oncotarget; 2017 Mar; 8(10):16642-16649. PubMed ID: 28186965
[TBL] [Abstract][Full Text] [Related]
2. Plasma ALU-247, ALU-115, and cfDNA Integrity as Diagnostic and Prognostic Biomarkers for Breast Cancer.
Hussein NA; Mohamed SN; Ahmed MA
Appl Biochem Biotechnol; 2019 Mar; 187(3):1028-1045. PubMed ID: 30151636
[TBL] [Abstract][Full Text] [Related]
3. Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer.
Kamel AM; Teama S; Fawzy A; El Deftar M
Tumour Biol; 2016 Jun; 37(6):7565-72. PubMed ID: 26684805
[TBL] [Abstract][Full Text] [Related]
4. Blood-based DNA methylation as biomarker for breast cancer: a systematic review.
Tang Q; Cheng J; Cao X; Surowy H; Burwinkel B
Clin Epigenetics; 2016; 8():115. PubMed ID: 27895805
[TBL] [Abstract][Full Text] [Related]
5. Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers.
Arko-Boham B; Aryee NA; Blay RM; Owusu EDA; Tagoe EA; Doris Shackie ES; Debrah AB; Adu-Aryee NA
Cancer Genet; 2019 Jun; 235-236():65-71. PubMed ID: 31105051
[TBL] [Abstract][Full Text] [Related]
6. Circulating DNA in Egyptian Women with Breast Cancer.
Ibrahim IH; Kamel MM; Ghareeb M
Asian Pac J Cancer Prev; 2016; 17(6):2989-93. PubMed ID: 27356723
[TBL] [Abstract][Full Text] [Related]
7. Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients.
Agostini M; Enzo MV; Bedin C; Belardinelli V; Goldin E; Del Bianco P; Maschietto E; D'Angelo E; Izzi L; Saccani A; Zavagno G; Nitti D
Cancer Biomark; 2012; 11(2-3):89-98. PubMed ID: 23011155
[TBL] [Abstract][Full Text] [Related]
8. Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer.
Zhang K; Luo Z; Zhang Y; Zhang L; Wu L; Liu L; Yang J; Song X; Liu J
Cancer Biomark; 2016 Jun; 17(2):187-94. PubMed ID: 27540977
[TBL] [Abstract][Full Text] [Related]
9. Circulating Plasma Tumor DNA.
Parsons HA; Beaver JA; Park BH
Adv Exp Med Biol; 2016; 882():259-76. PubMed ID: 26987539
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation array analyses identified breast cancer-associated HYAL2 methylation in peripheral blood.
Yang R; Pfütze K; Zucknick M; Sutter C; Wappenschmidt B; Marme F; Qu B; Cuk K; Engel C; Schott S; Schneeweiss A; Brenner H; Claus R; Plass C; Bugert P; Hoth M; Sohn C; Schmutzler R; Bartram CR; Burwinkel B
Int J Cancer; 2015 Apr; 136(8):1845-55. PubMed ID: 25213452
[TBL] [Abstract][Full Text] [Related]
11. Combined detection of plasma miR-127-3p and HE4 improves the diagnostic efficacy of breast cancer.
Lu M; Ju S; Shen X; Wang X; Jing R; Yang C; Chu H; Cong H
Cancer Biomark; 2017; 18(2):143-148. PubMed ID: 27983524
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival.
Michaelidou K; Ardavanis A; Scorilas A
Breast Cancer Res Treat; 2015 Jul; 152(2):323-36. PubMed ID: 26099606
[TBL] [Abstract][Full Text] [Related]
13. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
Sirera R; Bremnes RM; Cabrera A; Jantus-Lewintre E; Sanmartín E; Blasco A; Del Pozo N; Rosell R; Guijarro R; Galbis J; Sánchez JJ; Camps C
J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717
[TBL] [Abstract][Full Text] [Related]
14. Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes.
Győrffy B; Bottai G; Fleischer T; Munkácsy G; Budczies J; Paladini L; Børresen-Dale AL; Kristensen VN; Santarpia L
Int J Cancer; 2016 Jan; 138(1):87-97. PubMed ID: 26174627
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and biological significance of microRNA-221 in breast cancer.
Eissa S; Matboli M; Sharawy A; El-Sharkawi F
Gene; 2015 Dec; 574(1):163-7. PubMed ID: 26253160
[TBL] [Abstract][Full Text] [Related]
16. Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?
Gingras I; Salgado R; Ignatiadis M
Curr Opin Oncol; 2015 Nov; 27(6):560-7. PubMed ID: 26335664
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer.
Ueo H; Sugimachi K; Gorges TM; Bartkowiak K; Yokobori T; Müller V; Shinden Y; Ueda M; Ueo H; Mori M; Kuwano H; Maehara Y; Ohno S; Pantel K; Mimori K
Br J Cancer; 2015 Apr; 112(9):1519-26. PubMed ID: 25880010
[TBL] [Abstract][Full Text] [Related]
18. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
19. Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer.
Shan M; Yin H; Li J; Li X; Wang D; Su Y; Niu M; Zhong Z; Wang J; Zhang X; Kang W; Pang D
Oncotarget; 2016 Apr; 7(14):18485-94. PubMed ID: 26918343
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a multiplex methylation specific PCR-coupled liquid bead array for liquid biopsy analysis.
Parisi C; Mastoraki S; Markou A; Strati A; Chimonidou M; Georgoulias V; Lianidou ES
Clin Chim Acta; 2016 Oct; 461():156-64. PubMed ID: 27510924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
